# Recurrent Atypical Fibroxanthoma in a 76-Year-Old Man Treated With Cryotherapy: A Case Report

**Authors:** Isaac Apichoto-Mata, Silvia Julieta García-Contreras, Brenda Garnica

PMC · DOI: 10.7759/cureus.102596 · Cureus · 2026-01-29

## TL;DR

A 76-year-old man with recurring atypical fibroxanthoma was successfully treated with cryotherapy after multiple surgeries failed.

## Contribution

This case report highlights cryotherapy as a potential treatment for recurrent atypical fibroxanthoma.

## Key findings

- AFX recurred in 2023 and 2024 despite adequate surgical excision.
- Cryotherapy resulted in a 12-month recurrence-free period.
- Non-surgical treatments may be effective for AFX management.

## Abstract

Atypical fibroxanthoma (AFX) is a rare cutaneous neoplasm that predominantly affects elderly individuals, typically arising on sun-exposed areas of the head and neck and exhibiting diverse clinical presentations. Histologically, it is composed of atypical spindle cells and is associated with intermediate-grade malignant potential. This case report describes a 76-year-old man diagnosed with recurrent AFX, initially presenting in 2022, with subsequent recurrences in 2023 and 2024 despite adequate excisional surgeries. The patient was ultimately treated with cryotherapy, achieving a 12-month recurrence-free period. Although surgical excision remains the gold standard, there are no universally accepted standardized therapies or guidelines for AFX management. Recent studies, however, have demonstrated the efficacy of non-surgical pharmacological treatments. This report highlights the diagnostic challenges and therapeutic complexities of recurrent AFX, particularly its propensity to mimic more aggressive malignancies.

## Full-text entities

- **Genes:** CD34 (CD34 molecule) [NCBI Gene 947], CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, DES (desmin) [NCBI Gene 1674] {aka CDCD3, CSM1, CSM2, LGMD1D, LGMD1E, LGMD2R}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, CD99 (CD99 molecule (Xg blood group)) [NCBI Gene 4267] {aka HBA71, MIC2, MIC2X, MIC2Y, MSK5X}
- **Diseases:** PDS (MESH:D012509), necrosis (MESH:D009336), basal cell carcinoma (MESH:D002280), squamous cell carcinoma (MESH:D002294), cutaneous lesions (MESH:D009059), AFX (MESH:D009437), bleeding (MESH:D006470), skin cancers (MESH:D012878), lung cancer (MESH:D008175), verrucous lesion (MESH:D018289), cutaneous neoplasm (MESH:D009369), dermatologic malignancies (MESH:D000168), undifferentiated pleomorphic sarcoma (MESH:D002277), soft tissue tumor (MESH:D012983), non-melanocytic melanoma (MESH:D008545), fibrosis (MESH:D005355), metastasis (MESH:D009362)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949712/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12949712/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949712/full.md

---
Source: https://tomesphere.com/paper/PMC12949712